DB
EVMN

Dmitry Balyasny’s Evommune Inc EVMN Stock Holding History

Dmitry Balyasny’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
+170,000
New +$3.95M ﹤0.01% 1756

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Dmitry Balyasny's EVMN Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Evommune Inc (EVMN) in Q2 2026: 457,015 shares worth $6.07M. The stake represents 0.01% of the portfolio and ranks #1290 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in EVMN as recently as Q4 2025.

Dmitry Balyasny first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Dmitry Balyasny held 457,015 shares of Evommune Inc worth $6.07M as of Q2 2026.
  • Evommune Inc was a new Dmitry Balyasny position in Q2 2026.
  • Evommune Inc made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1290 holding.
  • Dmitry Balyasny first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.